Sugi Predict

Sugi Predict / Compounds / SCHEMBL9606643

SCHEMBL9606643

SCHEMBL9606643

CCOC(=O)Cc1ccc(N)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ GFER P55789 1/20 0.45
▸ CYP4Z1 Q86W10 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MAOB P27338 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ KCNQ3 O43525 1/20 0.41
▸ KCNQ2 O43526 1/20 0.41
▸ KCNQ4 P56696 1/20 0.41
▸ KCNQ5 Q9NR82 1/20 0.41
▸ F10 P00742 1/20 0.41
▸ CYP4F2 P78329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4278414 0.89 ALDH1A1 (0.50) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2
SCHEMBL118588 0.85 ALDH1A1 (0.53) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2
SCHEMBL31287243 0.85 ALDH1A1 (0.53) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2
SCHEMBL165276 0.85 ALDH1A1 (0.50) ALDH1A1CYP4Z1SMN1; SMN2NPC1PKM
SCHEMBL11247614 0.85 CYP4F2 (0.56) ALDH1A1CYP4Z1KCNQ3KCNQ2KCNQ4
SCHEMBL5156693 0.84 SKP2 (0.49) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2
SCHEMBL30192992 0.84 ALDH1A1 (0.64) ALDH1A1GAAGFERSMN1; SMN2NPC1
SCHEMBL5957236 0.84 ALDH1A1 (0.64) ALDH1A1GAAGFERSMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL7256065 0.84 CYP4F2 (0.55) ALDH1A1CYP4Z1KCNQ3KCNQ2KCNQ4
SCHEMBL226654 0.83 YWHAG (0.50) ALDH1A1GAAGFERCYP4Z1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376056-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. 2024-11-14 — — US disclosed
EP-4366829-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF Dice Alpha, Inc. (US) 2024-05-15 — — EP disclosed
CN-117957212-A IL-17A modulators based on phenylacetamide and uses thereof 戴斯阿尔法公司 2024-04-30 — — CN disclosed
WO-2023283453-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-01-12 — — WO disclosed
US-20130261185-A1 Benzamide Derivatives As EP4 Receptor Agonists GLAXO GROUP LIMITED (GB) 2013-10-03 — — US disclosed
US-20130261185-A1 Benzamide Derivatives As EP4 Receptor Agonists GLAXO GROUP LIMITED (GB) 2013-10-03 — — US disclosed
WO-2013029338-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-03-07 — — WO disclosed
US-8314147-B2 Benzamide derivatives as EP4 receptor agonists GLAXO GROUP LIMITED (GB) 2012-11-20 — — US disclosed
US-8314147-B2 Benzamide derivatives as EP4 receptor agonists GLAXO GROUP LIMITED (GB) 2012-11-20 — — US disclosed
US-8252833-B2 Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists GLAXO GROUP LIMITED (GB) 2012-08-28 — — US disclosed
US-20090312388-A1 Benzo [F] Isoindoles As EP4 Receptor Agonists GLAXO GROUP LIMITED 2009-12-17 — — US disclosed
CN-101415678-A Benzo (F) isoindol-2-ylphenylacetic acid derivatives as EP4Receptor agonists GLAXO GROUP LTD (GB) 2009-04-22 — — CN disclosed
WO-2009019281-A1 BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN GLAXO GROUP LIMITED (GB) 2009-02-12 — — WO disclosed
US-20080167377-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2008-07-10 — — US disclosed
WO-2008071736-A1 BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-06-19 — — WO disclosed
WO-2008020055-A1 NOVEL ISOINDOL DERIVATIVES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-02-21 — — WO disclosed
WO-2008012344-A1 NAPHTHALENE DERIVATIVES USED AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-01-31 — — WO disclosed
WO-2008012347-A1 BENZO [F] ISOINDOLES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-01-31 — — WO disclosed
WO-2007088189-A1 BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN GLAXO GROUP LIMITED (GB) 2007-08-09 — — WO disclosed
WO-2007088190-A1 BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2007-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167377-A1 Novel compounds F12, C1R, MRGPRX1 ALDH1A1 2581/4885GAA 2128/4885GFER 4740/4885
US-20240376056-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF IL17A, IL1A, IL2 ALDH1A1 74/4885GAA 1019/4885GFER 2586/4885
US-20090312388-A1 Benzo [F] Isoindoles As EP4 Receptor Agonists PTGER4, GPR4, PTGER1 ALDH1A1 1617/4885GAA 4643/4885GFER 1698/4885
US-20130261185-A1 Benzamide Derivatives As EP4 Receptor Agonists PTGER4, PTGER1, PTGER3 ALDH1A1 1228/4885GAA 3892/4885GFER 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.